India
· Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 959.68 billion. The enterprise value is 1.02 trillion.
| Market Cap | 959.68B |
| Enterprise Value | 1.02T |
Important Dates
The next estimated earnings date is Thursday, July 31, 2025.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mankind Pharma has 412.73 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | 412.73M |
| Shares Outstanding | 412.73M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | +2.62% |
| Owned by Insiders (%) | 57.72% |
| Owned by Institutions (%) | 18.80% |
| Float | 106.03M |
Valuation Ratios
The trailing PE ratio is 47.37 and the forward PE ratio is 45.77. Mankind Pharma's PEG ratio is 3.09.
| PE Ratio | 47.37 |
| Forward PE | 45.77 |
| PS Ratio | 7.86 |
| PB Ratio | 6.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 49.15 |
| P/OCF Ratio | 39.76 |
| PEG Ratio | 3.09 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.82, with an EV/FCF ratio of 52.48.
| EV / Earnings | 51.47 |
| EV / Sales | 8.39 |
| EV / EBITDA | 33.82 |
| EV / EBIT | 42.54 |
| EV / FCF | 52.48 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.58.
| Current Ratio | 1.23 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.82 |
| Debt / FCF | 4.36 |
| Interest Coverage | 5.58 |
Financial Efficiency
Return on equity (ROE) is 16.62% and return on invested capital (ROIC) is 9.12%.
| Return on Equity (ROE) | 16.62% |
| Return on Assets (ROA) | 7.54% |
| Return on Invested Capital (ROIC) | 9.12% |
| Return on Capital Employed (ROCE) | 10.85% |
| Revenue Per Employee | 6.25M |
| Profits Per Employee | 1.02M |
| Employee Count | 19,540 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.91 |
Taxes
In the past 12 months, Mankind Pharma has paid 5.10 billion in taxes.
| Income Tax | 5.10B |
| Effective Tax Rate | 20.26% |
Stock Price Statistics
The stock price has increased by +3.11% in the last 52 weeks. The beta is 0.49, so Mankind Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +3.11% |
| 50-Day Moving Average | 2,449.57 |
| 200-Day Moving Average | 2,525.74 |
| Relative Strength Index (RSI) | 34.46 |
| Average Volume (20 Days) | 329,648 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 122.07 billion and earned 19.91 billion in profits. Earnings per share was 49.20.
| Revenue | 122.07B |
| Gross Profit | 87.18B |
| Operating Income | 23.97B |
| Pretax Income | 25.16B |
| Net Income | 19.91B |
| EBITDA | 30.18B |
| EBIT | 23.97B |
| Earnings Per Share (EPS) | 49.20 |
Balance Sheet
The company has 22.45 billion in cash and 85.11 billion in debt, giving a net cash position of -62.66 billion or -151.82 per share.
| Cash & Cash Equivalents | 22.45B |
| Total Debt | 85.11B |
| Net Cash | -62.66B |
| Net Cash Per Share | -151.82 |
| Equity (Book Value) | 145.68B |
| Book Value Per Share | 347.44 |
| Working Capital | 13.25B |
Cash Flow
In the last 12 months, operating cash flow was 24.13 billion and capital expenditures -4.61 billion, giving a free cash flow of 19.53 billion.
| Operating Cash Flow | 24.13B |
| Capital Expenditures | -4.61B |
| Free Cash Flow | 19.53B |
| FCF Per Share | 47.31 |
Margins
Gross margin is 71.42%, with operating and profit margins of 19.63% and 16.31%.
| Gross Margin | 71.42% |
| Operating Margin | 19.63% |
| Pretax Margin | 20.61% |
| Profit Margin | 16.31% |
| EBITDA Margin | 24.72% |
| EBIT Margin | 19.63% |
| FCF Margin | 16.00% |
Dividends & Yields
Mankind Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.07% |
| FCF Yield | 2.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |